Core Viewpoint - Four Seasons Pharmaceutical (00460) experienced a nearly 9% increase in stock price, closing at 1.75 HKD, following the announcement of its product approval by the National Medical Products Administration of China [1] Group 1: Product Approval - The company’s subsidiary, Meiyan Space Biotechnology (Jilin) Co., Ltd., received a Class III medical device registration certificate for its self-developed injectable transparent sodium hyaluronate composite solution, branded as "Dongyan" [1] - "Dongyan" is the first approved compound solution in China that contains L-carnosine, designed for temporary improvement of skin dryness and dull complexion [1] Group 2: Strategic Product Matrix - The approval of "Dongyan" marks another milestone for Meiyan Space, following the earlier launches of "Tongyan Injection" and "Shaonian Injection" within the year [1] - The company is building a strategic product matrix that combines compliant regenerative materials (Tongyan and Shaonian injections) with skin quality management (water light needle) as dual engines [1] Group 3: Market Position - Meiyan Space has over thirty approved products, establishing a comprehensive product layout in the light medical beauty sector [1] - The company has achieved an integrated layout from skin quality improvement to contour modification, reinforcing its leading position in comprehensive anti-aging solutions [1]
港股异动 | 四环医药(00460)尾盘涨近9% 旗下渼颜空间“冻妍”获国家药监局批准上市